Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E, Kouspou M, Eliades A, Papadopoulou K, Bournakis E, Goussia A, Tsiatas M, Achilleos A, Tsangaras K, Billioud G, Loizides C, Lemesios C, Kypri E, Ioannides M, Koumbaris G, Levva S, Vakalopoulos I, Paliouras A, Pervana S, Koinis F, Bumci R, Christopoulou A, Meditskou S, Psyrri A, Boukovinas I, Visvikis A, Karavasilis V, Koukoulis GK, Kotsakis A, Giannakis D, Fountzilas G, Patsalis PC. Fountzilas E, et al. Among authors: karavasilis v. Int J Mol Sci. 2023 Jul 23;24(14):11834. doi: 10.3390/ijms241411834. Int J Mol Sci. 2023. PMID: 37511593 Free PMC article.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020.
Bogogiannidou Z, Speletas M, Vontas A, Nikoulis DJ, Dadouli K, Kyritsi MA, Mouchtouri VA, Mina P, Anagnostopoulos L, Koureas M, Karavasilis V, Nikou O, Pinaka O, Thomaidis PC, Kadoglou K, Bedevis K, Spyrou N, Eleftheriou AA, Papaevangelou V, Gikas A, Vatopoulos A, Ntzani EE, Prezerakos P, Tsiodras S, Hadjichristodoulou C. Bogogiannidou Z, et al. Among authors: karavasilis v. Vaccines (Basel). 2021 May 13;9(5):504. doi: 10.3390/vaccines9050504. Vaccines (Basel). 2021. PMID: 34068100 Free PMC article.
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
Schöffski P, Toulmonde M, Estival A, Marquina G, Dudzisz-Śledź M, Brahmi M, Steeghs N, Karavasilis V, de Haan J, Wozniak A, Cousin S, Domènech M, Bovée JVMG, Charon-Barra C, Marreaud S, Litière S, De Meulemeester L, Olungu C, Gelderblom H. Schöffski P, et al. Among authors: karavasilis v. Eur J Cancer. 2021 Jul;152:26-40. doi: 10.1016/j.ejca.2021.04.015. Epub 2021 May 29. Eur J Cancer. 2021. PMID: 34062484 Free article. Clinical Trial.
Genotyping data of routinely processed matched primary/metastatic tumor samples.
Kotoula V, Chatzopoulos K, Papadopoulou K, Giannoulatou E, Koliou GA, Karavasilis V, Pazarli E, Pervana S, Kafiri G, Tsoulfas G, Chrisafi S, Sgouramali H, Papakostas P, Pectasides D, Hytiroglou P, Pentheroudakis G, Fountzilas G. Kotoula V, et al. Among authors: karavasilis v. Data Brief. 2020 Dec 11;34:106646. doi: 10.1016/j.dib.2020.106646. eCollection 2021 Feb. Data Brief. 2020. PMID: 33365374 Free PMC article.
Genotype-phenotype associations in colorectal adenocarcinomas and their matched metastases.
Chatzopoulos K, Kotoula V, Koliou GA, Giannoulatou E, Papadopoulou K, Karavasilis V, Pazarli E, Pervana S, Kafiri G, Tsoulfas G, Chrisafi S, Sgouramali H, Papakostas P, Pectasides D, Hytiroglou P, Pentheroudakis G, Fountzilas G. Chatzopoulos K, et al. Among authors: karavasilis v. Hum Pathol. 2021 Jan;107:104-116. doi: 10.1016/j.humpath.2020.10.009. Epub 2020 Nov 5. Hum Pathol. 2021. PMID: 33161028
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
Gennatas S, Chamberlain F, Carter T, Slater S, Cojocaru E, Lambourn B, Stansfeld A, Todd R, Verrill M, Ali N, Jones RL, Simmonds P, Keay N, McCarty H, Strauss S, Karavasilis V, Dileo P, Benson C. Gennatas S, et al. Among authors: karavasilis v. Clin Sarcoma Res. 2020 May 6;10:9. doi: 10.1186/s13569-020-00131-x. eCollection 2020. Clin Sarcoma Res. 2020. PMID: 32391141 Free PMC article.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators. Petrylak DP, et al. Lancet Oncol. 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0. Epub 2019 Nov 18. Lancet Oncol. 2020. PMID: 31753727 Free PMC article. Clinical Trial.
104 results